Pfizer

BORTEZOMIB

Manufacturer:

Pfizer

Bortezomib HCPCS:

J9044

HCPCS Code Descriptor:

Injection, bortezomib, not otherwise specified, 0.1 mg

Category:

J Code

Bortezomib NDCs:

No actively aligned NDCs found

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Bortezomib:

BORTEZOMIB is an Oncology drug manufactured by Pfizer and administered via the Subcutaneous route of administration. The J Code: J9044 is aligned to the drug BORTEZOMIB.

ACCESS PRICING AND MORE BY REGISTERING

J9044 Added Date:

January 1, 2019

J9044 Effective Date:

January 1, 2023

J9044 Termination Date:

December 31, 2022

We have not yet identified a manufacturer source of Bortezomib billing and coding information.
Bortezomib patient assistance information can be found through KabiCare at the URL: https://kabicare.us/
BORTEZOMIB prescribing information can be found at the link below:
Information regarding BORTEZOMIB’s side effects can be found at MedlinePlus